Molecular Partners' Ensovibep Shows Early Safety Profile In COVID-19

  • Molecular Partners AG MOLN announced the presentation of results from the Phase 2a study of ensovibep for COVID-19 patients and additional data from the Phase 1 study in healthy volunteers at the virtual European Scientific Working Group on Influenza (ESWI) Conference.
  • The single-arm Phase 2a study enrolled 12 patients with mild to moderate COVID-19 symptoms. 
  • First ensovibep data from COVID-19 infected patients at 225 mg and 600 mg doses were seen to be safe and well-tolerated.
  • No disease enhancement, related infusion reactions, or dose-limiting toxicities were observed.
  • Viral load data (qPCR) showed a comparable decline for both dose levels.
  • Infectivity of virus extracted through nasopharyngeal swabs was reduced to zero within 3-5 days post-treatment in patients with positive titers at baseline.
  • Related Link: See Why Molecular Partners Shares Dropped To 52-Week Low During Tuesday Premarket?
  • Global Phase 2/3 EMPATHY trial for ambulatory COVID-19 patients is ongoing, with topline data available in early 2022.
  • Molecular Partners also presented additional data from the Phase 1 study of intravenously administered ensovibep, which indicated that it was well tolerated with a half-life in the range of 2-3 weeks.
  • Price Action: MOLN shares closed lower by 1.91% at $13.35 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsCOVID-19 CoronavirusPhase 1 TrialPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!